Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 13/20 | 0.69 |
| ▸ | HRH1 | P35367 | 13/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491638 | 0.96 | HRH3 (0.92) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL492028 | 0.96 | HRH3 (0.92) | HRH3MAOBHRH2HRH1KDM4E | |
| Oxalic Acid SCHEMBL5856199 | 0.92 | HRH3 (0.86) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL7245910 | 0.89 | HRH3 (0.80) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL7244767 | 0.88 | HRH3 (0.78) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL7245066 | 0.88 | HRH3 (0.78) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL7242885 | 0.87 | HRH3 (0.77) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL7243987 | 0.86 | HRH3 (0.75) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL7252564 | 0.86 | HRH3 (0.76) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL13904318 | 0.84 | HRH3 (0.73) | HRH3MAOBHRH2HRH1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | claimed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | claimed |
| EP-1863486-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-12 | — | — | EP | claimed |
| WO-2006103537-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-10-05 | — | — | WO | claimed |
| EP-1707203-A1 | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | claimed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | claimed |
| US-8486947-B2 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2013-07-16 | — | — | US | disclosed |
| US-8106041-B2 | Combination product comprising an antagonist or inverse agonist of histamine receptor H3 and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-7910605-B2 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2011-03-22 | — | — | US | disclosed |
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | BIOPROJET (FR) | 2006-09-21 | — | — | US | disclosed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | disclosed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | HRH3 6/4885MAOB 111/4885HRH2 22/4885 |
| US-20060210624-A1 | Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs | HRH3, HRH4, HRH2 | HRH3 1/4885MAOB 580/4885HRH2 3/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | HRH3 1/4885MAOB 736/4885HRH2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.